Articles related to GUIDELINES/RECOMMENDATIONS

These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE)  – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.

The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.

The American Society of Hematology (ASH) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations toward the treatment of venous thromboembolism (VTE). The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events.

According to an international task force at the virtual PAINWeek meeting, chronic pain patients can be treated with medical cannabis following one of three protocols based on patient characteristics. The recommendations are timely considering the limited clinician knowledge about medical cannabis treatment and the opioid crisis.

Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Discover what the American Society of Hematology (ASH) recommends for your older adult AML patients.